Cambridge Healthtech Institute’s 4th Annual
Targeting Epigenetic Readers and Chromatin Remodelers
Targeting Protein-Protein Interactions of Epigenetic Readers
Part of the 14th Annual Discovery on Target Conference
September 21-22, 2016 | Westin Boston Waterfront | Boston, MA
Targeting epigenetic modifiers and readers, particularly histone methyltransferases, demethylases and bromodomain-containing proteins have recently set the foundation for a new generation of anti-cancer drugs. Over the past few years, several companies have developed and successfully moved novel compounds targeting EZH2, DOT1L, LSD1, and a collection of BET bromodomain inhibitors into clinical studies. As these compounds continue to progress, developers are now focused on the discovery of new targets and designing novel inhibitors to expand into this robust target space. Of particular interest for discovery are non-BET bromodomain proteins, chromodomain proteins, and methyl-lysine readers, arginine methyltransferases, and JmjC-domain containing demethylases.
Cambridge Healthtech Institute has extensively covered the progression of second-generation epigenetic inhibitor discovery and development by establishing the first and longest running series of meetings specifically focused on enhancing epigenetic drug discovery. We are once again excited to host the industry’s largest drug discovery event focused on targeting the chromatin-modifying enzymes of histone methyltransferases, demethylases and bromodomain-containing proteins. The back-to-back Targeting Histone Methyltransferases and Demethylases and Targeting Epigenetic Readers and Chromatin Remodelers meetings will once again unite academic and industry researchers to discuss novel tools and strategies for targeting these proteins, share the discovery and development of novel inhibitors, as well and provide an updates on preclinical and clinical findings.
Part 2 - Targeting Epigenetic Readers and Chromatin Remodelers
The second part of this seres focuses on one of the most recent and exciting areas of discovery research, centering around targeting chromatin modifying proteins, particularly those responsible for the recognition of the histone code written in acetyl and methyl marks. With several clinical trials underway, and countless discovery programs initiated, particular interest has been given to targeting the BET family of proteins across a diverse range of therapeutic indications.
Topics may include, but are not limited to:
Target Identification and Validation
- Novel Reader Targets with Therapeutic Implications in Cancer and Inflammation
- Novel Chromatin Remolding Targets with Therapeutic Implications in Cancer and Inflammation
Discovery to Lead
- Targeting Chromatin Remodelers, BET Bromodomains, Non-BET Bromodomains, and Methyl-Lysine Readers: PHD, Tudor, Chromo, PWWP, WD and MBT Domains
- Structural Characterization of Reader Domains and Remodeler Subunits
- High-Throughput Profiling and Screening for Inhibitors
- Virtual Screening
- Phenotypic Screening
- Fragment/Structure-Based Design
- Protein-Protein Interaction Strategies
- Development of High-Quality Chemical Probes/Scaffolds
- Discovery of Novel BET and Non-BET inhibitors
- Lead Optimization
- Dual Inhibitors
Pre-Clinical and Clinical Development
- Preclinical Studies on Novel Inhibitors Targeting Readers/Remodeler Subunits
- Updates on BET Bromodomain Programs in Preclinical and Clinical Stages
- Toxicology Studies
If you are interested in speaking, please click here.
Click here to register for a special early-bird discounted rate.
The deadline for submission is March 4, 2016.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Cambridge Healthtech Institute
T: (+1) 781-972-5454
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483